IFNL3 and head and neck squamous cell carcinoma: Consistent with this notion, the restrained rates of head and neck squamous cell carcinoma in mice treated with recombinant IL-28B and cisplatin were thought to be associated with tumor-specific CTL-mediated and NK-medicated antitumor activities [21].